Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 728 participants.
Also called NCT05065216
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 728 participants
- Sponsor
- DiaMedica Therapeutics Inc
- Registry
-
NCT05065216
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Belgium, Canada, France, Georgia, Hungary, Poland, Romania, Spain, United Kingdom
- Registry status
- Recruiting
Technical summary
Registry record NCT05065216. Randomized; double masking; primary purpose treatment. Start 2021-11-07 (actual); primary completion 2026-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
- Acronym
- ReMEDy2
- Condition
- Acute Stroke
- Condition
- Ischemic Stroke
- Condition
- Stroke
- Intervention (Drug)
- Recombinant human tissue kallikrein
- Intervention (Other)
- Placebo for DM199 Solution for Injection
- Lead sponsor
- DiaMedica Therapeutics Inc
Record details
- Record id
cardio:ct-nct05065216- Content hash
9b283a4fe21e76eca0fb72a72af064daad330d1974bd5b68ac284abd6370f0f9